Compounds with dual CYP24A1 inhibition and VDR activation were also demonstrated to ameliorate SHPT in a dose-dependent manner in uremic rats with efficient reduction of plasma PTH at doses that did not elevate serum calcium or phosphate, suggesting potential usefulness in human CKD. This evidence concerns the gene CYP24A1 and chronic kidney disease.